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Experiments were performed to evaluate the
hypothesis that the early stage of Type 1 dia-
betes mellitus (DM) increases renal angiotensin
II (AngII) concentration and angiotensin type 1
(AT1) receptor protein levels. Nineteen or twen-
ty days after vehicle (Sham rats) or streptozo-
tocin (STZ rats) treatment, plasma [AngII] was
higher in STZ rats (152±23 fmol/ml) than in
Sham rats (101±7 fmol/ml); however, kidney
[AngII] did not differ between groups. AT1
receptor protein expression was greater in STZ
kidneys than in Sham kidneys. This increase
was restricted to the cortex, where AT1 protein
levels were elevated by 77±26% (42 kDa) and
101±16% (58 kDa) in STZ kidneys.
Immunohistochemistry revealed this effect to
be most evident in distal nephron segments
including the connecting tubule/cortical col-
lecting duct. Increased renal cortical AT1 recep-
tor protein and circulating AngII levels are con-
sistent with an exaggerated AngII-dependent
influence on renal function during the early
stage of DM in the rat.
Key words: angiotensin II; immunohistochem-
istry; rat; renal cortex; streptozotocin
INTRODUCTION
Angiotensin converting enzyme inhibition is
widely recognized to retard development of
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1560-4284/02 $12.00 + .00glomerular injury in Type 1 (insulin-dependent)
diabetes mellitus (DM) [1]. Moreover, chronic
treatment with an angiotensin type 1 (AT1)
receptor antagonist can prevent diabetic hyper-
filtration (4-6 wk after onset) and eventual
development of proteinuria and glomeruloscle-
rosis (1 yr after onset) in rats with streptozo-
tocin (STZ)-induced DM [2]. While these
observations suggest that angiotensin II
(AngII)-dependent mechanisms contribute to
development of diabetic nephropathy, the pre-
cise derangements in AngII regulation of renal
function in DM remain poorly defined. 
Biochemical studies attempting to character-
ize the status of the renin-angiotensin system
(RAS) in DM have yielded conflicting data, in
part because it has only recently become appar-
ent that the intrarenal RAS and the systemic
RAS can be differentially regulated. In the early
stages of STZ-induced DM, renal angiotensino-
gen levels are either reduced [3] or normal [6].
Although plasma renin activity is typically
decreased in the early stages of DM, renal renin
activity is variably reported to be elevated [5],
normal [3,6] or reduced [7,8]. Moreover,
despite normal or reduced total renal
angiotensin converting enzyme activity [5,7,9],
immunostaining for this enzyme is enhanced in
glomeruli and the renal vasculature during
STZ-induced DM [5]. The literature contains
reports that STZ-treated rats exhibit unaltered
plasma AngII levels [10,11], while renal AngII
levels are either unchanged [10,12] or dimin-
ished [11]. In severely hyperglycemic models of
DM in the rat, binding studies suggest that
renal AngII receptor density is decreased [6,13,
14], while AT1 receptor mRNA has been
reported to be either increased or decreased
[15,16]. Thus, the accumulated biochemical
and molecular evidence is equivocal with
regard to the status of the intrarenal RAS in
DM.
Circulating and local AngII concentrations
and AT1 receptor protein expression at specific
effector sites are prime determinants of the
renal functional impact of the RAS. Most of the
existing data concerning plasma and renal
AngII levels in DM were obtained from anes-
thetized animals, in which activation of the
RAS may confound the data interpretation.
Moreover, few studies have attempted to quan-
tify or localize alterations in the AT1 receptor
protein within the kidney during DM. The
present experiments were performed to test the
hypothesis that DM increases renal AngII con-
centration and AT1 receptor levels, and to iden-
tify the intrarenal site(s) at which AT1 receptor
expression is altered.
MATERIALS AND METHODS
ANIMAL PREPARATION
The procedures used in this study were
approved by the University of Nebraska
Medical Center Institutional Animal Care and
Use Committee. DM was induced in male
Sprague-Dawley rats weighing 261±8 g
(SAS:VAF strain; Charles River Laboratories,
Wilmington, MA) by a single injection of STZ
(65 mg/kg, iv), with moderate hyperglycemia
maintained by subcutaneous implantation of a
sustained-released insulin pellet (Linplant  ;
Linshin Canada, Scarborough, Ontario). Both
of these procedures have been detailed previ-
ously [17]. Sham rats received vehicle treat-
ments. The rats were housed in pairs and
allowed ad libitum access to food and water.
Blood glucose concentration and body weight
were measured at 3-4 day intervals. 
Nineteen or twenty days after induction of
DM, the animals were decapitated and tissues
were harvested for biochemical studies. For
assessment of plasma AngII levels, trunk blood
was collected into chilled tubes containing
100% methanol. A blood sample was also
taken for hematocrit determination. Blood
samples were centrifuged at 4  C for 10 min at
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stored at –20  C. The right kidney of each rat
was used for measurement of AngII levels.
Upon excision, this kidney was quickly
drained, weighed, immersed in cold methanol
and homogenized with a glass homogenizer.
Renal homogenization was begun 74±2 s after
decapitation, a delay previously found not to
significantly alter measured angiotensin peptide
levels [18]. In half of the Sham and STZ ani-
mals, the left kidney was harvested for process-
ing renal AT1 receptor protein levels and local-
ization. A 3 mm mid-coronal section of this
kidney was reserved for immunohistochem-
istry, and the remaining tissue was stored at
–70  C until the time of protein extraction for
Western blot analysis of AT1 receptor protein.
In the other half of the Sham and STZ animals,
the left kidney was separated into renal cortex
and medulla prior to freezing, protein extrac-
tion and Western blot analysis.
ANGII LEVELS
Plasma and kidney AngII levels were meas-
ured by RIA using anti-AngII antibody
(Phoenix Pharmaceuticals, Belmont, CA),
monoiodinated  125I-labeled AngII (Amersham,
Arlington Heights, IL) and AngII standard as
previously reported [19]. Briefly, the kidney
supernatants were dried overnight in a vacuum
centrifuge. The dried residue was reconstituted
in 4 ml of 50 mM sodium phosphate buffer
(pH 7.4) containing 1 mM EDTA, 0.25 mM
thimerosal, and 0.25% heat-inactivated bovine
serum albumin (BSA). Plasma and kidney sam-
ples were extracted by absorption to a phenyl-
bonded solid-phase extraction column (Bond-
Elut; Varian, Harbor City, CA) and subsequent
elution with 100% methanol. The eluates were
collected and stored at –20  C. Before RIA, the
eluates were evaporated to dryness under vacu-
um and reconstituted in assay diluent (50 mM
sodium phosphate, 1 mM EDTA, 0.25 mM
thimerosal, 0.25% heat-inactivated BSA; pH
7.4). The reconstituted extracts were incubated
with AngII antiserum and 125I-AngII for 48 h at
4  C. Bound and free AngII were separated by
dextran-coated charcoal, and the supernatants
were counted by a computer-linked gamma
counter for 5 min. Results are reported in
fmol/g kidney weight or fmol/ml plasma. The
sensitivity of the AngII assay is <5 fmol/g. The
specific binding for AngII averaged 38%, with
a non-specific binding of 2%.
AT1 RECEPTOR PROTEIN ANALYSIS
Western Blot Analysis of Renal AT1
Receptor. Proteins were extracted from total
kidney, cortical and medullary tissues following
homogenization in buffer containing protease
inhibitors (1 µg/ml aprotinin, 100 µg/ml PMSF,
2 mM EDTA, 1 µg/ml leupeptin, 1 µM sodium
orthovanodate, 50 mM Tris, 150 mM NaCl,
0.2% sodium azide, 0.1% SDS, 1% nonidet
P40, and 0.5% sodium deoxycholate) and
assayed by the method of Lowry [20]. Kidney
samples (50 µg) were electrophoretically sepa-
rated by 3 to 10% stacking Tris-glycine gel at
100 V for 2 h (10% SDS, 24 mM Tris base, 192
mM glycine) and transferred (20% methanol,
12 mM Tris base, 96 mM glycine) to nitro-
cellulose membrane (0.45; Bio-Rad
Laboratories, Hercules, CA) for 90 min at 25 V
according to manufacturer specifications
(XCell II Mini-Cell; Novex, San Diego, CA). A
10-220 kDa protein ladder (GibcoBRL/Life
Technologies, Grand Island, NY) was used to
determine approximate molecular weight.
Kidney samples were separated in duplicate on
each of two gels. One gel was stained with
0.1% Coomassie blue R250 to visualize the
protein bands for total protein quantification
and confirmation of equal protein loading
between the groups. Western blot analysis was
performed as previously described [21]. Blots
were incubated with the primary polyclonal
anti-peptide AT1 antibody (1:200; 15-24 a.a.;
recognizes AT1A and AT1B subtypes; SC-1173;
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3 h, washed, incubated with the secondary
antibody conjugated to horseradish peroxidase
(1:1500) for 1 h, and washed. For preadsorp-
tion studies, the polyclonal antibody was incu-
bated overnight at 4  C in the presence of the
synthetic peptide antigen (20 µg, SC-1173P;
Santa Cruz). Detection was accomplished using
enhanced chemiluminescence Western blotting
(ECL; Amersham) and the blots were exposed
to X-ray film (Hyperfilm-ECL; Amersham).
Bands were quantified by scanning laser densit-
ometry (Ultroscan; Pharmacia LKB, Uppsala,
Sweden).
Immunohistochemical Localization of
Renal AT1 Receptor. Kidneys from Sham and
STZ rats were prepared by immersion fixation
in 10% buffered formalin overnight, dehydrat-
ed, embedded in paraffin blocks and sectioned
at a thickness of 5 µm. Each slide contained
two consecutive kidney sections, one of which
was incubated with antipeptide AT1 monoclon-
al antibody (undiluted 6313/G2; 8-17 a.a.; rec-
ognizes AT1A and AT1B subtypes, G. P. Vinson)
while the other was incubated with non-
immune mouse serum (negative control), as
previously described [22]. Immunostaining was
detected using the immunoperoxidase tech-
nique (Vectastain ABC; Vector Laboratories,
Burlingame, CA) with diaminobenzidine as the
chromogen. Sections were counterstained with
hematoxylin and lithium carbonate. Extreme
care was taken to ensure that the time of fixa-
tion, incubation with primary and secondary
antibodies, chromogen, and counterstains was
identical for each slide. We previously docu-
mented that omission of the secondary anti-
body or preadsorption with the antigenic pep-
tide abrogates renal vascular and tubular AT1
receptor immunostaining using this monoclon-
al antibody [22]. 
STATISTICAL ANALYSES
Results are expressed as means±SEM. The
data were analyzed using unpaired or paired t-
test, as appropriate. Statistical significance was
defined at a value of P<0.05.
RESULTS
ANIMAL CHARACTERISTICS
Blood glucose concentration averaged 88±1
mg/dl (n=19) in Sham and STZ rats at day zero
(immediately prior to STZ or vehicle injection).
Twenty-four hours after injection, all STZ rats
were verified to display blood glucose concen-
trations >300 mg/dl before implantation of sus-
tained release insulin pellets. During the ensu-
ing 19-20 days, blood glucose levels averaged
271±14 mg/dl (n=9) in STZ rats, but remained
at 80±1 mg/dl (n=10) in Sham animals. Body
weight increased 78±6 g in Sham rats, but only
28±5 g in STZ rats during this period. Right
kidney weight was greater in STZ rats
(1474±63 mg) than in Sham rats (974±28 mg;
P<0.001). Accordingly, right kidney
weight/body weight ratios were significantly
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FIGURE 1
Comparison of plasma and kidney AngII levels in Sham
(hatched bars) and STZ rats (solid bars). Values are
means±SE. *P < 0.05 vs. Sham.higher in STZ rats (4.5±0.2 mg/g) than in Sham
rats (3.2±0.1 mg/g; P<0.001), indicating the
renal hypertrophy characteristic of DM.
Hematocrit did not differ between groups
(Sham 0.49±0.01; STZ 0.49±0.01). 
ANGII LEVELS
The effects of DM on plasma and renal
AngII levels are summarized in Figure 1.
Plasma AngII levels were significantly elevated
by ~50% in STZ rats compared with Sham ani-
mals. In contrast, renal AngII levels did not dif-
fer between Sham and STZ rats. Consequently,
while the plasma-to-kidney AngII concentra-
tion ratio averaged 0.92±0.11 g/ml in Sham
rats (n=8), this value was doubled in STZ rats
(1.88±0.26 g/ml, n=10; P<0.005). 
AT1 RECEPTOR PROTEIN ANALYSIS
Western Blot Analysis of Renal AT1
Receptor. Western blot analysis of kidney pro-
tein demonstrated two predominant
immunoreactive proteins with estimated molec-
ular weights of 42 and 58 kDa. Both bands
were displaced by preadsorption of the primary
antibody with the synthetic peptide antigen
(Figure 2). An additional 47 kDa band not fully
displaced by the peptide antigen was consid-
ered to represent non-specific binding.
Quantitative analysis of renal AT1 receptor
expression was determined by Western blot of
total kidney, cortical and medullary protein
extracts from Sham (n=5) and STZ (n=3–5)
rats. This analysis was repeated 3-4 times for
each sample, and statistical analysis was per-
formed using sample means. AT1 receptor pro-
tein levels were significantly elevated in total
kidney protein extracts from STZ rats com-
pared with Sham rats (Fig. 3A), as evidenced by
a 53% increase in the 42 kDa protein and a
tripling of the 58 kDa protein. The increase in
AT1 protein expression was localized to the cor-
tex, where the 42 kDa receptor protein was
increased by 77% and the 58 kDa protein was
doubled in STZ rats (both P<0.05; Fig. 3B).
Medullary AT1 protein levels did not differ sig-
nificantly between the two groups (Fig. 3C).
Equal protein loading was confirmed by
Coomassie blue staining of duplicate gels, with
relative densitometric values averaging
1.09±0.09 and 1.00±0.08 in whole kidney
samples from STZ and Sham rats, respectively.
Similarly, Coomassie blue densitometry values
did not differ between groups of cortical sam-
ples (STZ 1.17±0.12; Sham 1.00±0.08) or
medullary samples (STZ 1.10±0.10; Sham
1.00±0.08). 
In a paired analysis, total AT1 receptor pro-
tein (42+58 kDa) was expressed at higher levels
in medulla than in cortex, such that medullary
levels averaged 227±36% of cortical levels.
Sham and STZ kidneys did not differ in this
regard. Moreover, medullary tissue expressed
predominantly the lower molecular weight
form of the AT1 protein, while the structures of
the cortex expressed predominantly the higher
molecular weight form of the receptor.
Medullary expression of the 42 kDa protein
was 537±95% of cortical levels (n=7), while
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FIGURE 2
Specificity of the AT1 receptor antibody. AT1 receptor pro-
tein was detected by Western blot analysis in total kidney
protein extract (50 µg/lane) using the polyclonal AT1 anti-
body (lane 1) or antibody preadsorbed with the immuno-
genic peptide (lane 2). Primary bands detected at 42 and
58 kDa with the primary antibody were eliminated by
preadsorption.medullary expression of the 58 kDa protein
was less than that observed in the cortex
(81±13% of cortical levels).
Immunohistochemical Localization of
Renal AT1 Receptor.  The AT1 receptor was
localized in Sham (n=5) and STZ (n=5) kidneys
using immunohistochemical techniques and the
relative intensity of immunostaining was
assessed in blinded fashion. Figure 4 illustrates
cortical and medullary AT1 immunostaining in
Sham and STZ kidneys. Sham and STZ kidneys
did not appear to differ with regard to AT1
immunostaining of afferent arteriolar vascular
smooth muscle, glomerular mesangial cells or
podocytes (Fig. 4A and 4B), or the smooth
muscle cells of larger arteries (data not shown).
In STZ kidneys, distal nephron segments resid-
ing in the cortex displayed a striking increase in
AT1 immunostaining intensity (Fig. 4D) relative
to that evident in Sham kidneys (Fig. 4C). The
increased immunostaining was most apparent
in connecting tubule/cortical collecting duct
segments, identified based on the prominence
of intercalated cells bulging into the lumen.
However, increased AT1 immunostaining was
sometimes evident in tubular segments contain-
ing nuclei situated very close to the apical mem-
brane and displaying apical flattening of the
nucleus, both of which are characteristic of dis-
tal convoluted tubule cells [23]. Proximal tubu-
lar immunostaining intensity was similar in
kidneys from STZ (Fig. 4B and 4D) and Sham
(Fig. 4A and 4C) rats. Consistent with the find-
ings by Western blot analysis, the intensity and
pattern of medullary AT1 receptor immunos-
taining appeared similar in STZ (Fig. 4F) and
Sham (Fig. 4E) rats, with inner medullary col-
lecting ducts representing the predominant
structures showing AT1 receptors. Figure 4G
represents a section incubated with non-
immune mouse serum (in the absence of pri-
mary antibody), confirming that cortical struc-
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FIGURE 3
Western blot analysis of kidney AT1 receptor protein levels in Sham rats (S, hatched bar) and rats with STZ-induced dia-
betes (D, solid bar) detected using the polyclonal antibody. Representative autoradiographs are shown above the corre-
sponding bar graph for total kidney (A), cortical (B), and medullary (C) protein extracts (50 µg protein/lane). Values are
means±SE. *P < 0.05 vs. Sham.tures including proximal tubules and interlobu-
lar artery do not show immunostaining under
these negative control conditions. 
DISCUSSION
Numerous investigators have postulated that
the RAS plays a pathophysiologic role in the
renal hemodynamic abnormalities that occur in
the early stage of DM, thereby contributing to
development of diabetic glomerulopathy.
Existing evidence concerning the status of the
intrarenal and circulating RAS in DM is
remarkably inconsistent and demonstrates no
clear trend related to duration of the disease or
severity of the hyperglycemic state [24]. The
present study employed a rat model of DM (19-
20 days after onset) that we have previously
demonstrated to display renal hyperperfusion
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FIGURE 4
Light photomicrographs illustrating the immunohistochemical distribution of AT1 receptors in kidneys from Sham
(A,C,E) and STZ rats (B,D,F,G). In the cortex (A-D), immunostaining for AT1 receptor protein was evident in
proximal tubules (PT) and connecting tubule/cortical collecting ducts (CD), with fainter staining of mesangial cells
and podocytes within glomeruli (Glom) and vascular smooth muscle cells in the arterioles (Art). AT1 receptor
immunoreactivity was more intense in connecting tubule/cortical collecting duct segments in kidneys from STZ
rats (D), compared with Sham rats (C). Immunostaining of cortical vascular structures did not appear to differ
between groups (A,B). Medullary AT1 receptor immunostaining was prominent in inner medullary collecting ducts
(*), and was of similar intensity in Sham (E) and STZ (F) animals. No immunoreactive signal was observed in neg-
ative control sections incubated with non-immune mouse serum (G). Bars represent 50 µm.and glomerular hyperfiltration [25]. These ani-
mals display moderate hyperglycemia (due to
the provision of partial insulin replacement),
renal hypertrophy, polydipsia and polyuria
[17,25,26]. The alterations in renal function
that accompany this model include afferent
arteriolar dilation associated with glomerular
hyperfiltration [25,27], and are markedly dis-
tinct from the increased afferent arteriolar
resistance and decreased glomerular filtration
rate evident in more severely hyperglycemic
models of DM in the rat [27,28]. Because of the
widely recognized ability of angiotensin con-
verting enzyme inhibition to ameliorate hyper-
filtration in DM, we restricted our observations
to the moderately hyperglycemic model known
to display hyperfiltration. 
Our observation that hematocrit did not dif-
fer between Sham and STZ rats indicates no
substantial alteration in extracellular fluid vol-
ume status that might be anticipated to activate
or suppress the RAS. Nevertheless, plasma
AngII levels measured by RIA were elevated in
STZ rats compared with Sham rats. Because
anesthesia is widely recognized to stimulate
renin release, AngII concentration was meas-
ured in tissue harvested immediately upon
decapitation in order to avoid any influence of
anesthesia that might confound or mask DM-
dependent changes in plasma AngII levels. In
accord with our data, Campbell et al. [12]
recently reported a tendency for increased plas-
ma AngII concentration (numerically twice
normal, but statistically insignificant) in sam-
ples obtained upon decapitation of moderately
hyperglycemic rats studied 4 wk after STZ
treatment. These observations contrast with
earlier reports of normal AngII levels in plasma
from anesthetized, moderately hyperglycemic
rats studied 6-8 wks after STZ treatment
[10,11]. Time-related alterations in the sys-
temic RAS during the course of DM might also
contribute to disparities in the effect of DM on
plasma AngII levels. Despite the increase in cir-
culating AngII observed in STZ rats, renal
AngII levels did not differ significantly between
groups in the present study. This observation is
consistent with reports that renal AngII levels
are either normal [10,12,29] or decreased [11]
in moderately hyperglycemic STZ rats. Our
finding of increased circulating AngII levels in
association with unaltered renal AngII levels
further affirms that intrarenal levels of the pep-
tide can be regulated independent of circulating
levels [18,30]. 
An additional component of the present
study was the quantification and localization of
renal AT1 receptor protein in kidneys from
Sham and STZ rats. While the AT1 receptor has
a predicted molecular weight of 41 kDa based
on the cDNA sequence, Western blot analysis
using the polyclonal antibody against the AT1
receptor detected two major bands (42 and 58
kDa) that were eliminated by preadsorption
with the immunogenic peptide. Other investi-
gators have also detected ~40 and ~60 kDa
immunoreactive proteins using antibodies
directed to similar regions of the AT1 receptor
protein [31,32]. It is intriguing to note that the
higher molecular weight form of the receptor
(58 kDa, representing the glycosylated protein)
predominated in the cortex while the lower
molecular weight form of the receptor (42 kDa,
corresponding to the non-glycosylated protein)
predominated in the medulla. The functional
significance of this observation is uncertain as
the absence of N-glycosylation markedly sup-
presses trafficking of the receptor to the cell
membrane while having no effect on ligand
binding in COS-7 cells expressing mutagenized
AT1 cDNA [33,34]. Although AT1 receptor
mRNA is expressed at similar levels in cortex
and medulla [35], results of the present study
reveal that the AT1 receptor (42+58 kDa) con-
stitutes a substantially larger proportion of
total protein in medulla than in cortex. This
observation extends previous reports of high-
density AngII binding in the medulla of the nor-
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overall cortical binding [36].
Application of Western blot analysis to
whole kidney homogenates revealed that the
AT1 receptor protein was present at higher lev-
els in STZ rats than in Sham rats. Moreover, in
contrast with the recent report that renal corti-
cal AT1 receptor protein levels are reduced in
more severely hyperglycemic STZ rats [37],
results of the present study revealed a signifi-
cant increase in AT1 receptor protein in the cor-
tex of moderately hyperglycemic STZ rats
while no change was apparent in medullary
extracts. Because multiple cortical structures
express AT1 receptors and exhibit functional
responses to AngII, kidneys from Sham and
STZ animals were subjected to immunohisto-
chemical analysis to determine if the increase in
AT1 receptor protein was localized to vascular
or epithelial structures. These studies utilized
an anti-peptide monoclonal mouse anti-rat
antibody that, like the polyclonal antibody
used for Western blot analysis, recognizes both
AT1A and AT1B receptor subtypes [31]. Positive
immunostaining for the AT1 receptor was
found in proximal tubule brush border and
basolateral membranes, distal tubule, connect-
ing tubule/collecting duct, vascular smooth
muscle, mesangial cells, podocytes and macula
densa cells of rat renal cortex, similar to previ-
ous observations in our laboratory [22] and
others [38]. This pattern of AT1 receptor pro-
tein localization is in agreement with the iden-
tification of AT1 receptor mRNA in all nephron
segments by RT-PCR of microdissected struc-
tures from rat kidney [38,39,40].
Photomicrographs of immunohistochemical
tissue sections from each animal group were
observed in a blinded fashion by 3 investigators
(PKC, LHB, SED), each of whom noted that
sections from STZ kidneys exhibited increased
immunostaining in connecting tubule/cortical
collecting duct segments. There is a gradual
transition between distal nephron segments
within the renal cortex of the rat, including
some overlap of cell types [23]. Indeed, intense
AT1 immunostaining was sometimes evident in
cells displaying characteristics of distal convo-
luted tubule cells. While further study is neces-
sary to distinguish the exact tubular segment(s)
involved, it is at least apparent that distal
nephron segments residing within the cortex
represent a primary site of increased AT1 recep-
tor protein expression in STZ rats. 
Binding studies have suggested that AngII
receptor density is increased, decreased or unal-
tered in glomeruli and preglomerular vascula-
ture of rats with DM [4,6,41,42]. The equivo-
cal nature of DM-associated changes in
glomerular AT1 protein expression is further
indicated by the recent report of unaltered
glomerular expression of the glycosylated form
of the protein (53-kDa) in concert with
increased expression of the 41-kDa nongly-
cosolated protein in STZ rats [43]. No change
in immunostaining of either the glomeruli or
preglomerular microvasculature of STZ rats
was evident in the present study, although the
low intensity staining of these structures in nor-
mal rat kidney probably precluded our ability
to detect any decline in staining [22]. In con-
trast, although proximal tubular AT1 staining is
relatively robust using our immunostaining
procedure, the present study provided no evi-
dence of decreased staining intensity of this
tubular segment in kidneys from STZ rats. This
result is at variance with reports of decreased
specific  125I-AngII binding [44], AT1 mRNA
expression [44], and AT1 protein expression
[37] in the proximal tubule of rats with STZ-
induced DM. It is likely that the disparate
reports concerning the impact of DM on prox-
imal tubular AT1 receptor expression reflect
variations on the STZ model, such as the pre-
cise insulin replacement regimen (or lack there-
of), the duration of DM, and/or the hyper-
glycemic status of the animals. 
Insulin exposure (24-48 hrs) stimulates
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angiotensinogen production and AT1 receptor
mRNA expression in cultured vascular smooth
muscle cells [45,46]. The effect of insulin on
AT1 receptor mRNA expression is associated
with increased Bmax (no change in Kd) and aug-
mented [Ca2+]i responses to exogenous AngII
[45], indicating an increase in functional AT1
receptors. These reports raise the possibility
that chronic insulin administration via the sus-
tained-release pellet could have contributed to
the increased plasma AngII and renal AT1 pro-
tein levels observed in the STZ rats. However,
STZ rats receiving insulin pellet implantation
according to the regimen employed in the pres-
ent study have plasma insulin levels averaging
approximately 40% of Sham rats (unpublished
observations). Because insulin levels are
decreased (rather than increased) in our STZ
rats, a direct effect of the chronic insulin
administration cannot explain the increased
renal AT1 receptor protein and circulating
AngII levels observed in these animals. 
No previous studies have suggested that DM
alters AT1 receptor expression in the distal
nephron. However, the change evident in the
cortical collecting duct/connecting tubule was
unmistakable in the present study and likely
represents the primary site of the increased cor-
tical AT1 receptor protein documented by
Western blot. Several alterations in distal
nephron protein expression have been reported
recently to accompany DM, including a decline
in the vasopressin-regulated urea transporter of
the inner medullary collecting duct [47], an
increase in the thiazide-sensitive NaCl co-trans-
porter of the distal convoluted tubule and con-
necting tubule [48], and increases in aquapor-
ins 2 and 3 [49]. This situation suggests that
DM provokes previously unappreciated func-
tional alterations in the distal nephron, perhaps
reflecting a compensatory response to the
osmotic diuresis. Because AngII influences api-
cal transport mechanisms at distal nephron
sites [50,51], the apparent increase in AT1
receptor protein in the cortical structures of the
distal nephron may act to conserve sodium and
maintain fluid balance during the chronic state
of increased urine flow in early DM. This
process would be facilitated by the attendant
increase in plasma AngII levels during DM.
However, no data are available concerning dis-
tal nephron transport in STZ rats or the func-
tional impact of AngII in this situation.
Increased plasma AngII and renal tubular AT1
receptor protein levels may also advance the
plasma volume expansion and elevated
exchangeable sodium frequently associated
with DM, thus representing an inappropriate
activation the intrarenal RAS [24]. 
In summary, the results of the present study
indicate that despite normal renal and
increased circulating endogenous AngII levels,
renal cortical AT1 receptors are upregulated
during the early (hyperfiltration) stage of DM
in the rat. This effect appears to be most
prominent in distal nephron segments residing
in the cortex, with no alteration apparent at
vascular sites. Further studies are necessary to
establish the underlying mechanisms and func-
tional consequences of these observations.
However, assuming that the increase in AT1
receptor protein expression reflects an increase
in functional receptors that are coupled to
intracellular pathways, these changes can be
expected to augment AngII-dependent influ-
ences on renal function and may also con-
tribute to the growth-promoting processes that
engender the eventual development of diabetic
nephropathy. 
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